{"schema_version":"secwatch.filing_event.v1","accession":"0001126234-24-000059","form_type":"8-K","ticker":null,"cik":"0001126234","company_name":"LUMOS PHARMA, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.374199+00:00","generated_at":"2026-06-01T22:37:45.739934+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lumos Pharma positive FDA End-of-Phase 2 meeting; Phase 3 trial plan with placebo control","bullets":["FDA agreed placebo-controlled design for LUM-201 Phase 3 trial; 2:1 randomization, ~150 patients, 6-month placebo arm.","Updated Phase 2 data show durable AHV: 12-month 8.2 cm/yr, 24-month 7.3 cm/yr (1.6 mg/kg) vs baseline 4.7 cm/yr.","Cash $23.2M at March 31, 2024; expected to fund operations through Q3 2024; Q1 net loss $10.4M vs $7.3M year-ago.","Full 12-month OraGrowtH212 data and additional analyses to be presented at ENDO in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001126234-24-000059","json":"https://secwatch.observer/filing/0001126234-24-000059.json","markdown":"https://secwatch.observer/filing/0001126234-24-000059.md","text":"https://secwatch.observer/filing/0001126234-24-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/0001126234-24-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/lumo-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:37:45.739934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cb7aa02e1f7b383f4897a8f387f99786f880906","claim":"LUMOS PHARMA, INC. reported the quarter ended March 31, 2024 results: net income $10.4 million.","evidence_excerpt":"Net Loss – The net loss for the quarter ended March 31, 2024, was $10.4 million compared to a net loss of $7.3 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623424000059/0001126234-24-000059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$10.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}